Genomics

Genomic Characterization of Metastatic Castration Resistant Prostate Cancer

Biopsies of castration resistant prostate cancer metastases were subjected to whole genome sequencing (WGS), along with RNA-sequencing (RNA-Seq). The overarching goal of the study is to illuminate molecular mechanisms of acquired resistance to therapeutic agents, and particularly androgen signaling inhibitors, in the treatment of metastatic castration resistant prostate cancer (mCRPC). This study is made available on AWS via the NIH STRIDES Initiative.

Listed for discovery. Access is provided by the original publisher under its terms.

Data coverage

Access & permitted use

Review the publisher’s documentation for availability, eligibility and permitted uses, including commercial analysis, model training and redistribution.

NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies

Need help sourcing data?

Tell us your required fields, population, geography and time period. We can review suitable sources and licensing options.

Request sourcing help

Related data sources

Clinical trialsOpen API

ClinicalTrials.gov Study Records

Registered clinical studies, recruitment status, interventions, conditions, sponsors and reported results. Searchable structured records available through the ClinicalTrials.gov API.

ClinicalTrials.gov / U.S. National Library of Medicine

Drug safetyOpen API

FDA Drug Adverse Event Reports

Publicly releasable drug adverse event and medication error reports drawn from FAERS, provided as queryable JSON through openFDA.

U.S. Food and Drug Administration

Population healthPublic download

CDC BRFSS 2025 Survey Microdata

Annual U.S. behavioral risk-factor survey covering chronic conditions, health behaviors and preventive care. The 2025 release contains 356,158 survey records.

Centers for Disease Control and Prevention